ECM
RAPT

ExodusPoint Capital Management’s RAPT Therapeutics RAPT Stock Holding History

ExodusPoint Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,152
Closed -$428K – 1882
2023
Q4 		$428K Buy
2,152
+539
+33% +$66.7K ﹤0.01% 1075
2023
Q3 		$214K Buy
+1,613
New +$263K ﹤0.01% 1503
2023
Q1 		– Sell
-3,569
Closed -$565K – 2066
2022
Q4 		$565K Sell
3,569
-8,153
-70% -$1.3M 0.01% 1126
2022
Q3 		$2.26M Buy
11,722
+5,144
+78% +$973K 0.03% 750
2022
Q2 		$960K Buy
+6,578
New +$877K 0.01% 1099
2022
Q1 		– Sell
-827
Closed -$243K – 2594
2021
Q4 		$243K Sell
827
-1,168
-59% -$312K ﹤0.01% 1743
2021
Q3 		$496K Sell
1,995
-1,415
-41% -$374K 0.01% 1390
2021
Q2 		$867K Buy
3,410
+291
+9% +$54.4K 0.01% 1076
2021
Q1 		$554K Sell
3,119
-106
-3% -$17.5K 0.01% 1274
2020
Q4 		$509K Buy
3,225
+1,108
+52% +$241K 0.01% 1240
2020
Q3 		$545K Buy
+2,117
New +$470K 0.01% 965
2020
Q2 		– Sell
-1,735
Closed -$295K – 1984
2020
Q1 		$295K Buy
+1,735
New +$395K 0.02% 657

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ExodusPoint Capital Management's RAPT Position: Q1 2024 in Review

ExodusPoint Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 2,152 shares — an estimated $428K sold.

ExodusPoint Capital Management first reported a position in RAPT in Q1 2020 and held it in 12 quarters. The position peaked at $2.26M in Q3 2022. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • ExodusPoint Capital Management reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 2,152 RAPT Therapeutics shares in Q1 2024, an estimated $428K.
  • ExodusPoint Capital Management first reported a position in RAPT Therapeutics in Q1 2020 and held it in 12 quarters.
  • ExodusPoint Capital Management's RAPT Therapeutics position peaked at $2.26M in Q3 2022.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.